Pharma & Biotech
Outlook Therapeutics Puts Reimbursement Paperwork at the Center of Its LYTENAVA Commercial Push
The administrative machinery of US healthcare reimbursement rarely moves markets — but for Outlook Therapeutics, a single coding application now...
Bayer’s September Crossroads: A Courtroom Verdict and a Crop Science Rebound Converge
The calendar is tightening around Bayer from two directions at once. On September 14, a Missouri courtroom will host a...
Redcare Pharmacy’s Next CEO Brings Marketplace Pedigree — But the Share Price Is Still Searching for a Floor
The operational machinery at Redcare Pharmacy keeps humming even as the company's leadership question dominates investor attention. A new digital...
Evotec’s Pipeline Push Meets a Market Fixated on the Bottom Line
Evotec's announcement of a fresh oncology collaboration this week underscores a widening chasm between the company's scientific momentum and the...
Novo Nordisk’s Squeezed Middle: Price Concessions and a Fast-Moving Rival Test Investor Patience
The Danish pharmaceutical giant finds itself in an uncomfortable position these days: advancing on multiple regulatory fronts while its share...
Novo Nordisk’s Oral Wegovy Push Hits Germany and China as the Bull-Bear Battle Widens
The Danish pharma giant is placing its biggest strategic bet on a pill — but the market is still weighing...
BioNTech’s September Reckoning: A Factory Review, a Seoul Data Drop, and a Market Learning to Wait
The market's patience with BioNTech has rarely been tested quite like this. The German biotech is juggling a halted colorectal...
Evotec’s Boardroom Exit and New T-Cell Alliance Offer Little Respite as Shares Languish Near Record Lows
The departure of a key board member and the launch of a fresh oncology partnership have done little to shift...
BioNTech’s Contradictory Autumn: Cash Flows Fade, Patent Clouds Gather, and Seoul Becomes the Decider
The arithmetic of BioNTech's current market position makes for uncomfortable reading. Regulatory approvals arrived in duplicate this week, yet the...
Evotec’s Boardroom Shuffle and New Oncology Alliance Do Little to Dislodge a Stock Stuck Near Its Floor
The contrast at Evotec could hardly be starker. On one side, the Hamburg-based biotech is signing research partnerships at a...
Popular News
-
SunHydrogen Set for European Debut with Groundbreaking Technology
-
Walgreens Implements Deep Restructuring Following Private Buyout
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
